key: cord-0031815-vvy6y2x4
authors: Pillay, Samantha; Steingart, Karen R; Davies, Geraint R; Chaplin, Marty; De Vos, Margaretha; Schumacher, Samuel G; Warren, Rob; Theron, Grant
title: Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
date: 2022-05-18
journal: Cochrane Database Syst Rev
DOI: 10.1002/14651858.cd014841.pub2
sha: a742be0ea5f9bfb54a6c7b93161fd270b6da61dd
doc_id: 31815
cord_uid: vvy6y2x4

BACKGROUND: The World Health Organization (WHO) End TB Strategy stresses universal access to drug susceptibility testing (DST). DST determines whether Mycobacterium tuberculosis bacteria are susceptible or resistant to drugs. Xpert MTB/XDR is a rapid nucleic acid amplification test for detection of tuberculosis and drug resistance in one test suitable for use in peripheral and intermediate level laboratories. In specimens where tuberculosis is detected by Xpert MTB/XDR, Xpert MTB/XDR can also detect resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. OBJECTIVES: To assess the diagnostic accuracy of Xpert MTB/XDR for pulmonary tuberculosis in people with presumptive pulmonary tuberculosis (having signs and symptoms suggestive of tuberculosis, including cough, fever, weight loss, night sweats). To assess the diagnostic accuracy of Xpert MTB/XDR for resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin in people with tuberculosis detected by Xpert MTB/XDR, irrespective of rifampicin resistance (whether or not rifampicin resistance status was known) and with known rifampicin resistance. SEARCH METHODS: We searched multiple databases to 23 September 2021. We limited searches to 2015 onwards as Xpert MTB/XDR was launched in 2020. SELECTION CRITERIA: Diagnostic accuracy studies using sputum in adults with presumptive or confirmed pulmonary tuberculosis. Reference standards were culture (pulmonary tuberculosis detection); phenotypic DST (pDST), genotypic DST (gDST),composite (pDST and gDST) (drug resistance detection). DATA COLLECTION AND ANALYSIS: Two review authors independently reviewed reports for eligibility and extracted data using a standardized form. For multicentre studies, we anticipated variability in the type and frequency of mutations associated with resistance to a given drug at the different centres and considered each centre as an independent study cohort for quality assessment and analysis. We assessed methodological quality with QUADAS‐2, judging risk of bias separately for each target condition and reference standard. For pulmonary tuberculosis detection, owing to heterogeneity in participant characteristics and observed specificity estimates, we reported a range of sensitivity and specificity estimates and did not perform a meta‐analysis. For drug resistance detection, we performed meta‐analyses by reference standard using bivariate random‐effects models. Using GRADE, we assessed certainty of evidence of Xpert MTB/XDR accuracy for detection of resistance to isoniazid and fluoroquinolones in people irrespective of rifampicin resistance and to ethionamide and amikacin in people with known rifampicin resistance, reflecting real‐world situations. We used pDST, except for ethionamide resistance where we considered gDST a better reference standard. MAIN RESULTS: We included two multicentre studies from high multidrug‐resistant/rifampicin‐resistant tuberculosis burden countries, reporting on six independent study cohorts, involving 1228 participants for pulmonary tuberculosis detection and 1141 participants for drug resistance detection. The proportion of participants with rifampicin resistance in the two studies was 47.9% and 80.9%. For tuberculosis detection, we judged high risk of bias for patient selection owing to selective recruitment. For ethionamide resistance detection, we judged high risk of bias for the reference standard, both pDST and gDST, though we considered gDST a better reference standard. Pulmonary tuberculosis detection ‐ Xpert MTB/XDR sensitivity range, 98.3% (96.1 to 99.5) to 98.9% (96.2 to 99.9) and specificity range, 22.5% (14.3 to 32.6) to 100.0% (86.3 to 100.0); median prevalence of pulmonary tuberculosis 91.3%, (interquartile range, 89.3% to 91.8%), (2 studies; 1 study reported on 2 cohorts, 1228 participants; very low‐certainty evidence, sensitivity and specificity). Drug resistance detection People irrespective of rifampicin resistance ‐ Isoniazid resistance: Xpert MTB/XDR summary sensitivity and specificity (95% confidence interval (CI)) were 94.2% (87.5 to 97.4) and 98.5% (92.6 to 99.7) against pDST, (6 cohorts, 1083 participants, moderate‐certainty evidence, sensitivity and specificity). ‐ Fluoroquinolone resistance: Xpert MTB/XDR summary sensitivity and specificity were 93.2% (88.1 to 96.2) and 98.0% (90.8 to 99.6) against pDST, (6 cohorts, 1021 participants; high‐certainty evidence, sensitivity; moderate‐certainty evidence, specificity). People with known rifampicin resistance ‐ Ethionamide resistance: Xpert MTB/XDR summary sensitivity and specificity were 98.0% (74.2 to 99.9) and 99.7% (83.5 to 100.0) against gDST, (4 cohorts, 434 participants; very low‐certainty evidence, sensitivity and specificity). ‐ Amikacin resistance: Xpert MTB/XDR summary sensitivity and specificity were 86.1% (75.0 to 92.7) and 98.9% (93.0 to 99.8) against pDST, (4 cohorts, 490 participants; low‐certainty evidence, sensitivity; high‐certainty evidence, specificity). Of 1000 people with pulmonary tuberculosis, detected as tuberculosis by Xpert MTB/XDR: ‐ where 50 have isoniazid resistance, 61 would have an Xpert MTB/XDR result indicating isoniazid resistance: of these, 14/61 (23%) would not have isoniazid resistance (FP); 939 (of 1000 people) would have a result indicating the absence of isoniazid resistance: of these, 3/939 (0%) would have isoniazid resistance (FN). ‐ where 50 have fluoroquinolone resistance, 66 would have an Xpert MTB/XDR result indicating fluoroquinolone resistance: of these, 19/66 (29%) would not have fluoroquinolone resistance (FP); 934 would have a result indicating the absence of fluoroquinolone resistance: of these, 3/934 (0%) would have fluoroquinolone resistance (FN). ‐ where 300 have ethionamide resistance, 296 would have an Xpert MTB/XDR result indicating ethionamide resistance: of these, 2/296 (1%) would not have ethionamide resistance (FP); 704 would have a result indicating the absence of ethionamide resistance: of these, 6/704 (1%) would have ethionamide resistance (FN). ‐ where 135 have amikacin resistance, 126 would have an Xpert MTB/XDR result indicating amikacin resistance: of these, 10/126 (8%) would not have amikacin resistance (FP); 874 would have a result indicating the absence of amikacin resistance: of these, 19/874 (2%) would have amikacin resistance (FN). AUTHORS' CONCLUSIONS: Review findings suggest that, in people determined by Xpert MTB/XDR to be tuberculosis‐positive, Xpert MTB/XDR provides accurate results for detection of isoniazid and fluoroquinolone resistance and can assist with selection of an optimised treatment regimen. Given that Xpert MTB/XDR targets a limited number of resistance variants in specific genes, the test may perform differently in different settings. Findings in this review should be interpreted with caution. Sensitivity for detection of ethionamide resistance was based only on Xpert MTB/XDR detection of mutations in the inhA promoter region, a known limitation. High risk of bias limits our confidence in Xpert MTB/XDR accuracy for pulmonary tuberculosis. Xpert MTB/XDR's impact will depend on its ability to detect tuberculosis (required for DST), prevalence of resistance to a given drug, health care infrastructure, and access to other tests.

The World Health Organization (WHO) End TB Strategy stresses universal access to drug susceptibility testing (DST). DST determines whether Mycobacterium tuberculosis bacteria are susceptible or resistant to drugs. Xpert MTB/XDR is a rapid nucleic acid amplification test for detection of tuberculosis and drug resistance in one test suitable for use in peripheral and intermediate level laboratories. In specimens where tuberculosis is detected by Xpert MTB/XDR, Xpert MTB/XDR can also detect resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.

To assess the diagnostic accuracy of Xpert MTB/XDR for pulmonary tuberculosis in people with presumptive pulmonary tuberculosis (having signs and symptoms suggestive of tuberculosis, including cough, fever, weight loss, night sweats).

To assess the diagnostic accuracy of Xpert MTB/XDR for resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin in people with tuberculosis detected by Xpert MTB/XDR, irrespective of rifampicin resistance (whether or not rifampicin resistance status was known) and with known rifampicin resistance.

We searched multiple databases to 23 September 2021. We limited searches to 2015 onwards as Xpert MTB/XDR was launched in 2020.

Diagnostic accuracy studies using sputum in adults with presumptive or confirmed pulmonary tuberculosis. Reference standards were culture (pulmonary tuberculosis detection); phenotypic DST (pDST), genotypic DST (gDST),composite (pDST and gDST) (drug resistance detection).

Trusted evidence. Informed decisions. Better health.

Two review authors independently reviewed reports for eligibility and extracted data using a standardized form. For multicentre studies, we anticipated variability in the type and frequency of mutations associated with resistance to a given drug at the di erent centres and considered each centre as an independent study cohort for quality assessment and analysis. We assessed methodological quality with QUADAS-2, judging risk of bias separately for each target condition and reference standard. For pulmonary tuberculosis detection, owing to heterogeneity in participant characteristics and observed specificity estimates, we reported a range of sensitivity and specificity estimates and did not perform a meta-analysis. For drug resistance detection, we performed meta-analyses by reference standard using bivariate random-e ects models. Using GRADE, we assessed certainty of evidence of Xpert MTB/XDR accuracy for detection of resistance to isoniazid and fluoroquinolones in people irrespective of rifampicin resistance and to ethionamide and amikacin in people with known rifampicin resistance, reflecting real-world situations. We used pDST, except for ethionamide resistance where we considered gDST a better reference standard.

We included two multicentre studies from high multidrug-resistant/rifampicin-resistant tuberculosis burden countries, reporting on six independent study cohorts, involving 1228 participants for pulmonary tuberculosis detection and 1141 participants for drug resistance detection. The proportion of participants with rifampicin resistance in the two studies was 47.9% and 80.9%. For tuberculosis detection, we judged high risk of bias for patient selection owing to selective recruitment. For ethionamide resistance detection, we judged high risk of bias for the reference standard, both pDST and gDST, though we considered gDST a better reference standard. 

Review findings suggest that, in people determined by Xpert MTB/XDR to be tuberculosis-positive, Xpert MTB/XDR provides accurate results for detection of isoniazid and fluoroquinolone resistance and can assist with selection of an optimised treatment regimen. Given that Xpert

Xpert MTB/XDR, a rapid test for resistance to tuberculosis drugs Why is improving the diagnosis of tuberculosis drug resistance important?

Tuberculosis tests, like Xpert MTB/RIF, Xpert MTB/RIF Ultra, and Truenat, only diagnose rifampicin resistance, but do not provide information about resistance to other drugs used to treat tuberculosis. This information is needed to allow for e ective treatment to be started quickly.

Not recognizing tuberculosis drug resistance when present (false negative, FN) may result in severe illness and death. An incorrect diagnosis of tuberculosis drug resistance (false positive, FP) may result in stigma and prolonged and unnecessary treatment with less e ective drugs that have more side e ects.

How accurate is Xpert MTB/XDR for detecting pulmonary tuberculosis and resistance to tuberculosis drugs (i.e. isoniazid, fluoroquinolones, ethionamide, and amikacin) in adults?

What was studied in the review?

Xpert MTB/XDR is a rapid test for detecting tuberculosis and drug resistance in one test, suitable for laboratories that do not require advanced skills and infrastructure. We assessed Xpert MTB/XDR accuracy against three reference standards.

We identified two multicentre studies reporting on six separate cohorts (groups of study participants), 1228 participants for pulmonary tuberculosis detection and 1141 participants for drug resistance detection.

For pulmonary tuberculosis detection, we included two studies (one reporting on two separate cohorts). We did not determine an overall summary of Xpert MTB/XDR accuracy. 6 b We noted important di erences between the review question and the populations studied including prior testing with Xpert MTB/RIF and Xpert Ultra. The median prevalence in the included studies was not within the range of the three prevalence values provided in the Summary of findings table. We downgraded one level for indirectness. c For individual studies, specificity estimates ranged from 22% to 99%. We could in part explain the low specificity in one study by the small number of non-tuberculosis cases and that participants may have been receiving tuberculosis treatment (participants may have tested Xpert MTB/XDR positive and culture (reference standard) negative and be classified as false-positive). We downgraded one level for inconsistency. d We thought the range provided for true negatives and false positives would likely lead to di erent clinical decisions depending on which values were assumed. We downgraded one level for imprecision. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. Very low: we have very little confidence in the e ect estimate: the true e ect is likely to be substantially di erent from the estimate of e ect. The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.

Review question: what is the diagnostic accuracy of Xpert MTB/XDR for detection of isoniazid resistance? Population: adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin resistance status was known), detected as tuberculosis positive by Xpert All study cohorts were conducted in high multidrug-resistant/rifampicin-resistant tuberculosis burden countries. The median prevalence of fluoroquinolone resistance in the study cohorts was higher than the three prevalences listed in the GRADE table. Applicability to settings with lower prevalence of fluoroquinolone resistance comes with some uncertainty. Although the population for this question is 'irrespective of rifampicin resistance', we note that most participants had known rifampicin resistance. We did not downgrade for indirectness. This was a judgement. b Sensitivity estimates ranged from 83% (New Delhi) to 98% (Mumbai). Except for New Delhi, sensitivity was ≥ 91%. Regarding the low sensitivity estimate in New Delhi, heteroresistance and rare mutations at this site may in part explain the low sensitivity. We did not downgrade for inconsistency. c Specificity estimates were inconsistent: 84% (Mumbai), 91% (New Delhi), and ≥ 96% for other study cohorts. We could not explain the heterogeneity in specificity estimates. We downgraded one level inconsistency. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. 

High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. Very low: we have very little confidence in the e ect estimate: the true e ect is likely to be substantially di erent from the estimate of e ect. The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.

Review question: what is the diagnostic accuracy of Xpert MTB/XDR for detection of amikacin resistance? Population: adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis-positive by Xpert Cochrane Database of Systematic Reviews

A glossary of terms related to this Cochrane Review is provided in Appendix 1.

Tuberculosis continues to cause great su ering worldwide. Globally, in 2020, tuberculosis ranked second as the cause of death from a single infectious agent a er COVID-19; around 10 million people developed tuberculosis disease; and around 1.5 million people died (WHO Global Tuberculosis Report 2021 

In 2019, 13% of new tuberculosis cases and 17% of previously treated tuberculosis cases had isoniazid resistance (WHO Global Tuberculosis Report 2020), yet DST for isoniazid is o en only performed in people who are rifampicin resistant. Although in high MDR-TB settings the presence of rifampicin resistance alone has served as a proxy for MDR-TB and the basis for treatment decisions (Liu 2019; Nasiri 2018), emerging data suggest that in some settings, rifampicin DST has suboptimal specificity for MDR-TB. This means that testing for isoniazid resistance is increasingly important. For example, one study in the eastern Democratic Republic of the Congo found one in five people with rifampicin resistance to be isoniazid susceptible when tested using the GenoType MTBDR plus, a line probe assay (Bisimwa 2020). And the most recent South African National Survey of Drug Resistance found hotspots of rifampicin mono-resistance, where the prevalence ratio of such cases exceeded that of MDR-TB by up to 30% (NICD 2016).

Conversely, isoniazid resistance in the presence of rifampicin susceptibility (isoniazid mono-resistance) is also increasingly recognized as another emerging threat as it is associated with a three-fold increased risk of poor treatment outcomes and is an important enabler of MDR-TB (Espinal 2000). However, isoniazid resistance would be missed by molecular WHO-recommended diagnostic tests. DST for isoniazid is more complicated than for rifampicin owing to a greater variety of resistance-associated variants (including large deletions) across several genes (e.g. loci in katG, inhA, and ahpC) (WHO Catalogue of Mutations 2021). Information on these mutations may not be routinely available in lower resource settings.

Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews 

The target conditions are pulmonary tuberculosis and resistance to four tuberculosis drugs: isoniazid, fluoroquinolones, ethionamide, and amikacin.

Tuberculosis is caused by one of several bacterial species belonging to the Mycobacterium tuberculosis (M tuberculosis) complex of which the main human pathogen is M tuberculosis. Tuberculosis encompasses a dynamic spectrum, from latent infection to subclinical disease to active disease (Pai 2016). Tuberculosis in this review refers to active disease. Tuberculosis most commonly a ects the lungs (pulmonary tuberculosis) but may a ect any organ or tissue outside of the lungs, such as the brain or spine (extrapulmonary tuberculosis). Signs and symptoms of pulmonary tuberculosis typically include a persistent cough (for at least two weeks), fever, night sweats, weight loss, haemoptysis (coughing up blood), and fatigue, but may also be asymptomatic for prolonged periods of time (Frascella 2021). Tuberculosis is spread from person to person through the air. NAATs are molecular systems that can detect small quantities of genetic material DNA or ribonucleic acid (RNA)) extracted from micro-organisms, such as M tuberculosis, by amplifying regions of DNA or RNA to an amount large enough to study in detail. The key advantage of NAATs is that they are rapid diagnostic tests, potentially providing results in a few hours. A variety of molecular amplification methods are available, of which polymerase chain reaction (PCR) is the most common.

Low complexity refers to a situation where no special infrastructure is required and basic laboratory skills are suitable to run the test.

To run Xpert MTB/XDR, an initial manual specimen treatment step is needed in which sample reagent is added to the specimen. Sample reagent helps homogenize the specimen and prepare it for Library Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews in-cartridge DNA extraction. A 15-minute incubation period with occasional mixing by hand is required for homogenisation to be e ective. Subsequently, DNA extraction and PCR procedures are performed within the container linked to the diagnostic platform.

Several advantages of the assay have been described by the manufacturer.

• Faster time to result for detection of drug resistance.

• Results in less than 90 minutes.

• Similar easy-to-use process as Xpert MTB/RIF and Xpert MTB/RIF Ultra. • Run on existing GeneXpert platforms equipped with 10-colour modules.

The following information comes from the manufacturer's package insert (Cepheid package insert 2021). We note that in the package insert, 'MTB' refers to MTBC.

• Regarding isoniazid, Xpert MTB/XDR bases detection of resistance on mutations in the katG and fabG1 genes, oxyR -ahpC intergenic region, and inhA promoter region of the MTB genome. (The manufacturer acknowledges that reporting ethionamide resistance based only on the detection of mutations in the inhA promoter region is a known limitation that may limit sensitivity, though specificity may be una ected). • Regarding amikacin, Xpert MTB/XDR bases detection of resistance on mutations in the rrs region of the MTB genome.

When a second-line injectable drug is needed in a treatment regimen, amikacin is the preferred drug (WHO Consolidated Guidelines (Module 4) 2020). Although we prioritised the most important drug resistances to include based on guidance from the WHO, when a study included data for kanamycin or capreomycin resistance, we also reported Xpert MTB/XDR accuracy for detection of resistance to these drugs. • Scenario A. Xpert MTB/XDR used for detection of pulmonary tuberculosis and drug resistance. • Scenario B. Xpert MTB/XDR used for detection of drug resistance in people newly diagnosed with pulmonary tuberculosis by another test and whose rifampicin susceptibility is unknown. • Scenario C. Xpert MTB/XDR used for detection of drug resistance in people newly diagnosed with pulmonary tuberculosis and rifampicin resistance by other tests. • Scenario D. Xpert MTB/XDR used for detection of drug resistance in people being treated for pulmonary tuberculosis. We did not identify studies that assessed this role.

For each scenario, we expected direct testing (whereby Xpert MTB/ XDR is tested directly on a sputum specimen) to be favoured over indirect testing (whereby Xpert MTB/XDR is run on an M tuberculosis isolate grown from culture); however, indirect testing remains possible if, for example, direct testing initially failed.

The intended use setting is peripheral and intermediate level laboratories.

The downstream consequences of Xpert MTB/XDR testing include the following.

• TP (true positive): people would benefit from rapid diagnosis and early initiation of e ective tuberculosis treatment. • TN (true negative): people would be spared unnecessary treatment and would benefit from reassurance. For drug resistance detection, in particular, people would be more likely to be treated with more e ective drugs with fewer adverse events compared to drugs used to treat drug-resistant tuberculosis. Cochrane Database of Systematic Reviews risk of morbidity and mortality and there would be continued risk of transmission of tuberculosis and possibly drug-resistant tuberculosis in the community.

Before receiving Xpert MTB/XDR, people typically will have received testing with a WHO-recommended rapid diagnostic test to confirm tuberculosis.

The WHO recommends the role of Xpert MTB/XDR as a follow-on test a er tuberculosis is confirmed. In this role, Xpert MTB/XDR would be a replacement for line probe assays or culture-based phenotypic DST (pDST). In addition, Xpert MTB/XDR could be used in combination with existing tools that only test for rifampicin resistance, allowing detection of isoniazid-resistant, rifampicinsusceptible tuberculosis (WHO Consolidated Guidelines (Module 3) 2021). Xpert MTB/XDR could also be positioned as an initial test for detection of tuberculosis and drug resistance. We note that the timing of DST for rifampicin and other drugs can be before, in parallel, or a er Xpert MTB/XDR is performed, Figure 2 ,

Here we summarize selective alternative testing methods. The report 'Tuberculosis Diagnostics Pipeline Report: Advancing the Next Generation of Tools' describes additional tuberculosis tests and tests in development (Branigan 2021).

Mycobacterial culture is a method used to grow bacteria on nutrient-rich media. Culture-based DST requires growth of M tuberculosis in the presence of drugs at a specific concentration that will inhibit the growth of susceptible bacteria or have no impact on growth of resistant bacteria. Culture is a relatively complex and slow procedure. Solid culture typically takes between four to eight weeks for results, and liquid culture, although more sensitive and rapid than solid culture, requires up to six weeks and is more prone to contamination (Chihota 2010). In addition, culture requires specialized laboratories and highly skilled sta , rarely available in high tuberculosis burden countries. Culture is the reference standard for detection of pulmonary tuberculosis and the basis for pDST.

MeltPro kits (Xiamen Zeesan Biotech Co., Ltd., China) are commercially available, low-complexity tests for detection of mutations associated with resistance to rifampicin, isoniazid, fluoroquinolones, and injectable second-line drugs. Several of the available kits are approved by the China Food and Drug Administration for clinical use. MeltPro testing is designed to detect drug resistance on M tuberculosis-positive specimens or cultured isolates. MeltPro testing is performed using an all-in-one machine, Sanity 2.0. Manual pipetting is required for sample preparation, whereas the subsequent processes -nucleic acid extraction, sample loading, detection (i.e. real-time PCR), and interpretation of results -are all fully automatic. The detection of drug resistance is based on multicolor melting curve analysis. These tests are faster and simpler to perform than pDST and line-probe assays. Following the initial sample preparation step, these tests are mostly automated. The WHO recommends that 'in people with signs and symptoms of pulmonary tuberculosis, moderate complexity automated NAATs may be used on respiratory samples for the detection of pulmonary tuberculosis, and of rifampicin and isoniazid resistance, rather than culture and pDST (Conditional recommendation; moderate-certainty evidence for diagnostic accuracy)'. Moderate complexity automated NAATs are mainly suited for use in laboratory settings in areas with a high workload (i.e. high population density and high prevalence of tuberculosis). These tests require having a system for referring samples and reporting results (WHO Consolidated Guidelines (Module 3) 2021).

Alternative molecular methods for detection of drug resistance also include the commercial line probe assays, a category of genotypic (molecular) tests. Line probe assays include GenoType MTBDRplus assay (Bruker-Hain Lifescience, Nehren, Germany), and the Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan) for first-line tuberculosis drugs and GenoType MTBDRsl assay (Bruker-Hain Lifescience, Nehren, Germany) for second-line drugs. These methods have considerable advantages over pDST for scaling up programmatic management and surveillance of drug-resistant tuberculosis, o ering speed of diagnosis (one or two days), standardized testing, potential for high through-put, and fewer requirements for laboratory biosafety. Drawbacks are that line probe assays require skills and infrastructure only available in intermediate and central laboratories (WHO Operational handbook -diagnosis 2021).

Based on new evidence on the management of drug-resistant tuberculosis, the WHO has issued recommendations that all people with MDR/rifampicin-resistant tuberculosis, including those who are also resistant to fluoroquinolones, may benefit from alloral treatment regimens (WHO Consolidated Guidelines (Module 4) 2020). In people with tuberculosis and rifampicin-resistant tuberculosis it is critically important to perform additional resistance testing to at least isoniazid and the fluoroquinolones in order to guide treatment decisions. People with isoniazid monoresistant tuberculosis may also benefit from modified regimens that include fluoroquinolones. Information on inhA promotor mutations could also guide high-dose isoniazid therapy. Hence, rapid extended profiling of drug resistance could allow for early initiation of appropriate treatment and likely better patient outcomes. Amplification of drug resistance would also be less likely. Extended profiling of drug resistance could also be of importance in considering the use of the four-month fluoroquinolone-containing regimens for drug-susceptible tuberculosis (Dorman 2021). An allin-one rapid test to detect resistance to rifampicin and other drugs would be ideal; however, this technology is not currently available. 

• To assess the diagnostic accuracy of Xpert MTB/XDR for pulmonary tuberculosis in people with presumptive pulmonary tuberculosis. • To assess the diagnostic accuracy of Xpert MTB/XDR for resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin in people with tuberculosis detected by Xpert MTB/ XDR, irrespective of rifampicin resistance (whether or not their rifampicin resistance status was known) and with known rifampicin resistance.

Presumptive tuberculosis refers to an individual who presents with symptoms or signs suggestive of tuberculosis (WHO Definitions and Reporting 2020). Symptoms suggestive of tuberculosis include cough, fever, weight loss, and night sweats.

As a secondary objective, we planned to compare the diagnostic accuracy of Xpert MTB/XDR by direct testing (whereby Xpert MTB/ XDR is tested directly on a sputum specimen) versus indirect testing (whereby Xpert MTB/XDR is performed on a Mycobacterium tuberculosis (M tuberculosis) isolate grown from culture). However, owing to limited data, we narratively described these analyses and presented results in forest plots.

We planned to investigate the e ects of a number of potential sources of heterogeneity as outlined in our protocol, however, our ability to investigate these was limited by the available data. The sources of heterogeneity that we investigated were smear status (pulmonary tuberculosis detection) and type of reference standard, smear status, HIV status, and previous tuberculosis treatment (drug resistance detection).

We note that investigations in people previously treated for tuberculosis are important questions for clinical practice and studies have highlighted the challenges in interpreting the related tests, Xpert MTB/RIF (Theron 2016a) and Xpert MTB/RIF Ultra (Mishra 2020).

We included cross-sectional and cohort studies that assessed the diagnostic accuracy of Xpert MTB/XDR for both pulmonary tuberculosis and tuberculosis drug resistance, or tuberculosis drug resistance alone. We included diagnostic accuracy studies in which people with the target condition and people without the target condition were sampled from a single source population (referred to as a single-gate design) (Rutjes 2005). We only included studies that reported data comparing Xpert MTB/XDR to an acceptable reference standard (defined below) from which we could extract or derive TP, FP, FN, and TN values.

We included adults 15 years and older with presumptive pulmonary tuberculosis. In addition, we included adults with bacteriologicallyconfirmed pulmonary tuberculosis irrespective of rifampicin resistance (whether or not their rifampicin resistance status was known) and with known rifampicin resistance. We included HIVpositive and HIV-negative people. We included people who, at study enrolment, did not report previous tuberculosis treatment or reported receiving tuberculosis treatment. We included studies that assessed the diagnostic accuracy of Xpert MTB/XDR using sputum (expectorated or induced) consistent with the intended use of the manufacturer, and studies from all types of health facilities and all laboratory levels (peripheral, intermediate, and central) from all countries.

The index test was Xpert MTB/XDR. Xpert MTB/XDR tests for drug resistance a er testing has identified the presence of M tuberculosis in the specimen. Interpretation of results for Xpert MTB/XDR is shown in Figure 1 .

Before receiving Xpert MTB/XDR, people will have typically received testing verifying tuberculosis with another WHO-recommended rapid diagnostic test.

Some people detected as having tuberculosis by another WHOrecommended rapid diagnostic test may not be detected as having tuberculosis by Xpert MTB/XDR, We note that in comparison to related Xpert tests that detected tuberculosis, the limit of detection of Xpert MTB/XDR for M tuberculosis was 71.9 colony-forming units (CFU)/mL, similar to the limit of detection of Xpert MTB/RIF (86.9 CFU/mL), but above the limit of detection of Xpert MTB/RIF Ultra (15.6 CFU/mL) (Cao 2021; Chakravorty 2017).

The target conditions were pulmonary tuberculosis and resistance to four tuberculosis drugs: isoniazid, fluoroquinolones, ethionamide, and amikacin.

We included pulmonary tuberculosis as a target condition because some users of the Xpert MTB/XDR assay may want to do the test to detect pulmonary tuberculosis, in particular, in areas where isoniazid mono-resistance is also likely.

The reference standard for detection of pulmonary tuberculosis was solid or liquid culture or both solid and liquid culture.

• The presence of pulmonary tuberculosis was defined as a positive M tuberculosis culture. • The absence of pulmonary tuberculosis was defined as a negative M tuberculosis culture. 

We included three reference standards for detection of drug resistance, pDST, gDST, and a composite reference standard. These methods are used to determine whether M tuberculosis bacteria are susceptible or resistant to tuberculosis drugs.

• pDST alone.

• The presence of drug resistance was defined as drug resistance detected by pDST. • The absence of drug resistance for a given drug (referred to as being drug susceptible) was defined as drug resistance not detected by pDST.

We considered pDST to be the most suitable reference standard for detection of resistance to isoniazid, fluoroquinolones, and amikacin. pDST is the conventional method for detecting resistance to first-and second-line tuberculosis drugs.

• gDST alone.

• The presence of drug resistance was defined as drug resistance detected by gDST. • The absence of drug resistance was defined as drug resistance not detected by gDST.

We considered gDST to be the most suitable reference standard for ethionamide resistance because there is considerable overlap in the minimum inhibitory concentrations (MICs) of M tuberculosis isolates with and without resistance-causing variants and a pDST reference standard might not correctly classify the target condition.

• Composite reference standard.

• The presence of drug resistance was defined as drug resistance detected by either pDST or gDST. • The absence of drug resistance was defined as drug resistance not detected by both pDST and gDST.

The classification rule for the composite reference standard is based on one of the two reference tests (pDST or gDST) being positive for resistance to a given drug. Consequently, it is not necessary to perform a second reference standard test once the result of the first reference standard test is positive (resistant). Hence, the second reference standard test is only necessary in people with a negative (susceptible) or failed test result (e.g. indeterminate, contaminated) on the first reference standard test (Rutjes 2005). The composite reference standard result was considered drug susceptible when pDST reported drug susceptibility and gDST did not detect a drug-associated resistant mutation.

We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, ongoing) .

We searched the following databases up to 23 September 2021, without language restrictions, using the search terms and strategy described in Appendix 2. We limited our searches to 2015 onwards as Xpert MTB/XDR is a newly developed assay, which was launched in July 2020.

• Cochrane Infectious Diseases Group Specialized Register. 

We reviewed reference lists of included articles and any relevant review articles identified through the above methods. We also contacted researchers at the Foundation for Innovative New Diagnostics (FIND), the WHO Global Tuberculosis Programme, the manufacturer, and other experts in the field of tuberculosis diagnostics for information on ongoing and unpublished studies. We reviewed data submitted via the WHO public call.

We used Covidence to manage the selection of studies (Covidence). Two review authors independently screened titles and abstracts identified from literature searching to identify potentially eligible studies. We retrieved the article of any citation identified by one of the review authors for full-text review. Then, two review authors independently assessed articles for inclusion using predefined inclusion and exclusion criteria. We resolved disagreements by discussion with a third review author. We recorded all studies excluded a er full-text assessment and their reasons for exclusion in Characteristics of excluded studies. We illustrated the study selection process in a PRISMA diagram (Page 2021; Salameh 2020).

We developed a data extraction form based on experience with a previous Cochrane Review (Theron 2016b; Appendix 3). Two review authors independently extracted data on study design, participants, reference standards, and data required to populate a 2x2 contingency table. When possible, we extracted data for each study cohort within a multicentre study (see Statistical analysis and data synthesis). We resolved any discrepancies by discussion with a third review author. We entered the extracted data into an Excel database on password-protected computers. Data will be secured in the Liverpool School of Tropical Medicine 'Archive' drives of Cochrane Infectious Diseases Group for future review updates.

We extracted the following information.

• We classified country income status as low-income, middleincome, or high-income, according to the World Bank List of Economies (World Bank 2020). In addition, we classified 'country' as being high burden or not high burden for tuberculosis, HIV-associated tuberculosis, and MDR/rifampicinresistant tuberculosis based on the WHO classification for the period 2021-2025 (WHO Global Tuberculosis Report 2021). A country may be classified as high burden for one, two, or all three of the high burden categories.

We followed Cochrane policy, which states that, 'Anyone engaged in writing a Cochrane Review, who has had any involvement in the conduct, analysis, and publication of a study that could be included the review, is restricted in what they can do with those data. They CANNOT determine the overall study inclusion and exclusion criteria; and they CANNOT make study eligibility decisions about, extract data from, carry out the risk of bias assessment for, or perform GRADE assessments of that study'.

We used QUADAS-2 to assess methodological quality (Whiting 2011). QUADAS-2 consists of four domains: patient selection, index test, reference standard, and flow and timing. We assessed all domains for risk of bias and the first three domains for concerns regarding applicability. Two review authors independently completed QUADAS-2 and resolved disagreements through discussion, if needed, with a third review author. We presented the results of this quality assessment in text and figures. The tool tailored to this review is in Appendix 4.

We appraised methodological quality separately for each study cohort within a multicentre study and separately for each target condition. In addition, for drug resistance detection, in the reference standard domain, we considered risk of bias separately for each drug and each reference standard. This allowed us to assess whether the WHO-recommended critical concentration for the drug was used for the pDST reference standard and whether all relevant loci were included in the gDST reference standard.

For multicentre studies, we anticipated that there might have been variability in the frequency and types of mutations associated with resistance to a given drug at the di erent centres. For this reason, we considered each centre as an independent study cohort. We performed meta-analyses at the study cohort level, if data were available to take this approach.

We displayed key study characteristics in Characteristics of included studies. We plotted estimates of the observed sensitivities and specificities in forest plots with 95% confidence intervals (CIs) using Review Manager 5 (Review Manager 2020).

For detection of pulmonary tuberculosis, we narratively described the analysis and presented results in forest plots. Owing to heterogeneity in both the participant characteristics and observed specificity values, we did not perform a meta-analysis.

For detection of drug resistance, we took the following analytical approach. We stratified the analyses by type of testing (e.g. directly on sputum); population (irrespective of rifampicin resistance or known rifampicin resistance); target condition; and type of reference standard (pDST, gDST, and composite reference standard).

Within each analysis group (e.g. direct, irrespective of rifampicin resistance, isoniazid resistance, pDST), we plotted estimates of the observed sensitivities and specificities for each study cohort in forest plots with 95% CIs using Review Manager 5 (Review Manager 2020). Where adequate data were available, we combined data using meta-analysis by fitting a bivariate random-e ects model (Chu 2006; Macaskill 2010; Reitsma 2005) , using Stata (Version 14) with the metandi and meqrlogit commands (Stata). In situations with sparse data, we performed meta-analysis where appropriate by reducing the bivariate model to two univariate randome ects logistic regression models by assuming no correlation between sensitivity and specificity (Takwoingi 2017). When we observed little or no heterogeneity on forest plots, and the analyses consequently did not converge, we further simplified the models into fixed-e ect models by eliminating the random-e ects parameters for sensitivity or specificity, or both sensitivity and specificity (Takwoingi 2017). In situations where all study cohorts in a meta-analysis reported a sensitivity of 100% or specificity of 100%, we used simple pooling by summing the numbers of TPs and total resistant cases to calculate sensitivity or the numbers of TNs and total susceptible cases to calculate specificity, as required. In these situations when needed, we determined 95% CIs using the Newcombe-Wilson method (Newcombe 1998). We required data from at least four study cohorts for meta-analysis.

Regarding the fluoroquinolone drug class, we estimated test accuracy for the drug class as a whole against pDST, meaning that if there were documented resistance to a given fluoroquinolone, this would be interpreted as resistance to the whole fluoroquinolone class. We used this approach because the fluoroquinolones have high cross-resistance owing to variants within the gyrA hotspot region (Zignol 2016). We excluded non-determinate and indeterminate results from analyses of diagnostic test accuracy. We performed meta-analyses to estimate the summary proportion of non-determinate and indeterminate results using the metaprop command in Stata (Version 14) (Stata).

When data were available, we reported when the index test did not detect tuberculosis to begin with (missed cases), which could result in resistant cases not receiving a result, Appendix 5.

For each target condition, we investigated heterogeneity through visual examination of forest plots of sensitivity and specificity.

For Xpert MTB/XDR accuracy by smear status, we narratively described these analyses and presented results in forest plots (see Di erences between protocol and review).

For Xpert MTB/XDR accuracy by smear status, HIV status, and previous tuberculosis treatment, we narratively described these analyses and presented results in forest plots (see Di erences between protocol and review).

All covariates were categorical.

• Smear status, positive or negative.

• HIV status, positive or negative.

• Previous tuberculosis treatment or no previous tuberculosis treatment.

For resistance detection for isoniazid and fluoroquinolones in people irrespective of rifampicin resistance, we performed sensitivity analyses by repeating the meta-analyses and excluding the study (reporting on two study cohorts) sponsored by the manufacturer.

For resistance detection for ethionamide and amikacin in people with known rifampicin resistance, we did not perform sensitivity analyses because the main analyses included only one study (reporting on four study cohorts), which was not sponsored by the manufacturer.

We did not conduct formal assessment of publication bias using methods such as funnel plots or regression tests, because such techniques have not been helpful for diagnostic test accuracy studies (Macaskill 2010).

We assessed the certainty of evidence using the GRADE approach for diagnostic studies (Balshem 2011; Schünemann 2008; Schünemann 2016). As recommended, we rated the certainty of evidence as high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome (i.e. sensitivity and specificity), the certainty of evidence started as high when there were high-quality studies (cross-sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels). At least two review authors discussed judgements and applied GRADE using the following methods (GRADEpro GDT; Schünemann 2020a; Schünemann 2020b).

Risk of bias: we used QUADAS-2 to assess risk of bias.

Indirectness: we assessed indirectness in relation to the population (including disease spectrum), setting, intervention (index test), and outcomes (accuracy measures). We also use prevalence of the target condition as a guide to whether there was indirectness in the population.

Inconsistency: inconsistency can be caused by clinical heterogeneity or methodological heterogeneity, or it may remain unexplained. GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We had planned to carry out pre-specified analyses to investigate potential sources of heterogeneity and downgrade when we could not explain the inconsistency in the accuracy estimates. However, as mentioned above, data were insu icient to carry out most analyses. We looked at the individual point estimates in the forest plots and judged whether they were more or less the same, as well as the 95% CIs to see if they overlapped. Cochrane Database of Systematic Reviews from these calculations. Imprecision also depends on the number of participants included to determine sensitivity and specificity. We took note of the uncertainty around point estimates along with the number of participants providing those data. We acknowledge the judgement of imprecision is subjective.

Publication bias: we considered the comprehensiveness of the literature search and outreach to researchers in tuberculosis, the presence of only studies that produce precise estimates of high accuracy despite small sample size, and knowledge about studies that were conducted, but were not published.

We used GRADEpro (GRADEpro GDT) to create summary of findings tables for each target condition.

The summary of findings tables include the following details.

• The review question and its components, population, (prior tests), setting, index test(s), and reference standard. • Summary estimates of sensitivity and specificity and 95% CIs. • The number of included studies and participants contributing to the estimates of sensitivity and specificity. • Prevalences of the target condition with an explanation of why the prevalences have been chosen. • An assessment of the certainty of the evidence (GRADE).

• Explanations for downgrading, as needed.

Using GRADE, we assessed certainty of evidence of Xpert MTB/ XDR accuracy for detection of resistance to isoniazid and fluoroquinolones in people irrespective of rifampicin resistance and ethionamide and amikacin in people with known rifampicin resistance, reflecting real world situations. For detection of resistance to isoniazid, flouroquinolones, and amikacin, we used pDST as the reference standard (WHO TPP 2021). For detection of resistance to ethionamide, we used gDST as the reference standard.

We identified 2396 records from database searching. A er removal of 1206 duplicate records, we screened 1190 titles and abstracts for relevance to the review topic. Of these, we excluded 1163 and assessed 27 full-text reports against our inclusion criteria. We excluded all 27 reports for the following reasons: not the index test (n = 21); not a diagnostic accuracy study (n = 3); prototype test (n = 2); and extrapulmonary specimen (n = 1). We identified three records from other sources: one record from the manufacturer (Omar 2020); one record from the Foundation for Innovative New Diagnostics (FIND) (Penn-Nicholson 2021); and one record from additional citation screening (Cao 2021). Following assessment for eligibility, we excluded one report that evaluated Xpert MTB/XDR in both clinical specimens and cultured isolates and the data could not be disaggregated (Cao 2021). Hence, we included two studies reporting on a total of six independent study cohorts. Both studies used a cross-sectional study design. All study cohorts were in high multidrug-resistant/rifampicin-resistant tuberculosis burden countries (Omar 2020; Penn-Nicholson 2021). . Study flow diagram. *Two multicentre studies were included, one with two study cohorts and one with four study cohorts. Hence, we included six distinct study cohorts in the review. The following definitions are from Page 2021. Report: a document (paper or electronic) supplying information about a particular study. It could be a journal article, preprint, conference abstract, study register entry, clinical study report, dissertation, unpublished manuscript, government report, or any other document providing relevant information. Record: the title or abstract (or both) of a report indexed in a database or website (such as a title or abstract for an article indexed in Medline). Records that refer to the same report (such as the same journal article) are "duplicates"; however, records that refer to reports that are merely similar (such as a similar abstract submitted to two di erent conferences) should be considered unique.

See Characteristics of included studies and Table 1 .

Omar 2020 was a multicentre study that involved two study cohorts at centres in China (Omar 2020 China) and South Africa (Omar 2020 South Africa). The two study cohorts included a total of 530 participants, of whom 487 (91.9%) had tuberculosis verified by culture and 254 (47.9%) had rifampicin resistance. Xpert MTB/XDR and reference standard testing were performed at a central-level laboratory. Both study cohorts used archived raw sputum or concentrated sputum sediment specimens from participants who had been evaluated for pulmonary tuberculosis in inpatient and outpatient settings. Specimens that were culture positive or negative by LJ (Löwenstein-Jensen) medium or MGIT (Mycobacteria Growth Indicator Tube) were included.

Culture positive specimens were included if they met the following criteria:

• at least 1 mL of frozen sputum sediment or 2 mL of raw sputum was available; • results were available for smear microscopy and culture (MGIT and/or LJ); • the specimen had results from Xpert MTB/RIF or Xpert MTB/RIF Ultra testing; • the specimen had pDST results for isoniazid, fluoroquinolones, ethionamide, amikacin, kanamycin, and capreomycin; and • the specimen had gDST results (loci included in the gDST reference standard are listed below).

Culture negative specimens were included if at least 1 mL of frozen sputum sediment or 2 mL of raw sputum was available. Specimens that had previously thawed were excluded. The study enrolled participants who had symptoms suggestive of pulmonary tuberculosis (i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis) and a risk factor for drug-resistant tuberculosis as follows:

• previously received greater than one month of treatment for a prior tuberculosis episode; or • failing tuberculosis treatment with positive sputum smear or culture a er ≥ three months of a standard tuberculosis treatment; or • had close contact with a known drug-resistant tuberculosis case; or • newly diagnosed with MDR-TB within the last 30 days; or

• previously diagnosed with MDR-TB and failed tuberculosis treatment with a positive sputum smear or culture a er ≥ three months of a standard MDR-TB treatment regimen.

Participants received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those with a positive Xpert MTB/ RIF or Xpert MTB/RIF Ultra result and a clear rifampicin result (resistant or susceptible) were included. Culture-positive samples were tested by pDST (MGIT) for resistance to isoniazid, rifampicin, fluoroquinolones, ethionamide, amikacin, kanamycin, and capreomycin. Participants were also required to produce an adequate quantity (3 mL) of sputum.

For detection of drug resistance, both multicentre studies evaluated Xpert MTB/XDR against all three reference standards (i.e. pDST, gDST, and composite reference standard). Both multicentre studies included identical loci in the gDST reference standard: katG, inhA promoter, fabG1, ahpC-oxyR intergenic region, gyrA, gyrB, rrs, and eis promoter.

See Figure 4 . Regarding applicability for patient selection, we considered all study cohorts to have high concern as the included patients did not match the review question.

In the index test domain, we considered all study cohorts to have low risk of bias and low concern about applicability.

In the reference standard domain, we considered all study cohorts to have low risk of bias and low concern about applicability.

In the flow and timing domain, we considered all study cohorts to have low risk of bias.

Resitance to isoniazid, fluoroquinolones, and amikacin, Figure 5 . In the index test domain, we considered all study cohorts to have low risk of bias. Regarding applicability, for the index test domain, we considered all study cohorts to have low concern.

In the reference standard domain, for pDST and gDST, we considered all study cohorts have low risk of bias. Regarding applicability, for the reference standard domain, we considered all study cohorts to have low concern.

In the flow and timing domain, we considered all study cohorts to have low risk of bias.

Ethionamide resistance, Figure 6 . 

One study reporting on two study cohorts was sponsored by the manufacturer (Omar 2020 China; Omar 2020 South Africa). We performed sensitivity analyses by repeating the meta-analyses and excluding these study cohorts (see Sensitivity analyses).

For Xpert MTB/XDR accuracy for detection of pulmonary tuberculosis, we identified two studies. One study reported data for two study cohorts (Omar 2020 China; Omar 2020 South Africa), and one study reported data for the study as a whole (Penn-Nicholson 2021), Figure 7 . Xpert 

Forest plots for isoniazid resistance are presented in Figure 8 , fluoroquinolone resistance in Figure 9 , ethionamide resistance in Figure 10 , and amikacin resistance in Figure 11 . Xpert MTB/XDR summary sensitivity and specificity estimates for detection of drug resistance are presented in Table 2 . Figure 11 . Forest plots of Xpert MTB/XDR sensitivity and specificity by direct testing for amikacin resistance by population and reference standard. Study in the forest plots refers to a study cohort within a multicentre study. gDST = genotypic drug resistance testing; pDST = phenotypic drug resistance testing; TP = true positive; FP = false positive; FN = false negative; TN = true negative.

For detection of resistance to isoniazid and fluoroquinolones, Xpert MTB/XDR summary estimates for sensitivity and specificity were similar when di erent reference standards were used, both in people irrespective of rifampicin resistance and in people with rifampicin resistance. For detection of resistance to amikacin, Xpert MTB/XDR summary sensitivity estimates against gDST in the di erent populations were more variable.

We note that Xpert MTB/XDR sensitivity for detection of isoniazid resistance, Figure 8 , and amikacin resistance, Figure 11 was lower in New Delhi than in other study cohorts.

For detection of ethionamide resistance, Xpert MTB/XDR summary estimates for sensitivity varied when di erent reference standards were used. Specificity values were more consistent in these analyses. We also note that against both pDST and a composite reference standard, Xpert MTB/XDR sensitivity for detection of Cochrane Database of Systematic Reviews ethionamide resistance was lower in New Delhi and Mumbai than in Moldova and South Africa, Figure 10 .

Forest plots of Xpert MTB/XDR sensitivity and specificity estimates for detection of kanamycin and capreomycin resistance are presented in Appendix 6.

For detection of kanamycin resistance, Xpert MTB/XDR summary sensitivity estimates were similar to those for amikacin. For detecting capreomycin resistance, Xpert MTB/XDR summary sensitivity estimates were lower than those for other drugs. Summary specificity estimates were more consistent in these analyses, Table 2 .

One study compared Xpert MTB/XDR accuracy on sputum (direct testing) with cultured isolates (indirect testing) (Penn-Nicholson 2021). Data were not reported by study cohort. For each drug (isoniazid, fluoroquinolone, ethionamide, and amikacin), Xpert MTB/XDR accuracy for drug resistance by type of testing was similar, Appendix 7.

Data on inconclusive Xpert MTB/XDR results and missed cases are described in Appendix 5.

The summary proportion of Xpert MTB/XDR non-determinate results was estimated to be 2.90% (95% CI: 1.97% to 3.84%). The proportion of Xpert MTB/XDR non-determinate results following retesting was 0.2% (1/531) (Omar 2020) and 0.3% (2/709) (Penn-Nicholson 2021).

See Table 3 .

One study provided information on retesting following an Xpert MTB/XDR indeterminate result (Penn-Nicholson 2021). No specimens were indeterminate upon retesting for resistance to isoniazid, fluoroquinolone, and ethionamide. Of 657 specimens tested by Xpert MTB/XDR for amikacin resistance, 23 (3.5%) had indeterminate results and 1/23 was indeterminate upon retesting.

One study reported information about when Xpert MTB/XDR did not detect tuberculosis to begin with (missed cases) (Omar 2020). Results are summarized in Appendix 5.

One study assessed Xpert MTB/XDR accuracy for pulmonary tuberculosis in smear-positive and smear-negative sputum specimens (Omar 2020), Figure 7 . Data were not reported by study cohort. We note that Xpert MTB/XDR sensitivity in smear-negative specimens was higher than expected and may have been overestimated (see Discussion).

One study compared Xpert MTB/XDR sensitivity and specificity for drug resistance in smear-positive and smear-negative sputum specimens (Penn-Nicholson 2021). Data were not reported by study cohort. For a given drug (isoniazid, fluoroquinolone, ethionamide, and amikacin), Xpert MTB/XDR accuracy for detection of drug resistance was similar in smear-positive and smear-negative specimens, Appendix 8.

One study compared Xpert MTB/XDR sensitivity and specificity for drug resistance in HIV-positive and HIV-negative people (Penn-Nicholson 2021). Data were not reported by study cohort. For resistance to isoniazid and fluoroquinolones, Xpert MTB/XDR sensitivity was similar, while for resistance to ethionamide and amikacin, Xpert MTB/XDR sensitivity was higher in HIV-positive people than in HIV-negative people, Appendix 9. There were few resistant samples in the HIV-positive subgroup compared to the HIV-negative subgroups, which could account for this variability. Xpert MTB/XDR specificity was high and consistent in all analyses.

One study assessed Xpert MTB/XDR accuracy for detection of drug resistance in people with and without previous tuberculosis treatment (Penn-Nicholson 2021). Data were not reported by study cohort. There were no notable di erences in Xpert MTB/ XDR sensitivity or specificity for drug resistance in people who reported no previous tuberculosis treatment in the preceding 60 days versus those who reported receiving tuberculosis treatment in the preceding 60 days, Appendix 10.

Overall, the sensitivity analyses made little di erence to the findings, Table 4 .

This Cochrane Review summarizes the evidence on the diagnostic accuracy of Xpert MTB/XDR, a newly developed nucleic acid amplification test (NAAT) that detects pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. We identified two multicentre studies reporting on a total of six independent study cohorts and including 1228 participants for pulmonary tuberculosis detection and 1141 participants for drug resistance detection. Both studies took place in high MDR/ rifampicin-resistant tuberculosis burden countries. The review had notable limitations. For detection of pulmonary tuberculosis, in the patient selection domain, we judged all studies as having high risk of bias owing to selective participant recruitment. For detection of ethionamide resistance, in the reference standard domain, we judged high risk of bias for both phenotypic drug susceptibility testing (pDST) and genotypic drug susceptibility testing (gDST).

Trusted evidence. Informed decisions. Better health.

• For each drug, Xpert MTB/XDR summary sensitivity and specificity estimates were similar in people irrespective of rifampicin resistance and people with rifampicin resistance. However, we note that a high proportion of participants had known rifampicin resistance.

We were unable to perform most pre-specified analyses owing to sparse data. Xpert MTB/XDR could guide treatment decisions and allow for rapid initiation of e ective therapy, especially regarding the use of fluoroquinolones in people with drug-resistant tuberculosis. The use of Xpert MTB/XDR in people with rifampicinsusceptible tuberculosis could also improve the detection of isoniazid resistance. Furthermore, with the exciting advent of new rifapentine-based shortened regimens for drug-susceptible tuberculosis, with and without moxifloxacin (a fluoroquinolone), the potential impact of Xpert MTB/XDR has increased (Dorman 2021).

We found, based on our summary estimates, that Xpert MTB/XDR sensitivity and specificity met the minimal (lowest acceptable) criteria for WHO's target product profile (TPP) for drug susceptibility testing (DST) to be used at peripheral microscopy centres. However, there is considerable uncertainty in the estimates and the lower limits of the 95% CIs lie below the TPP targets (WHO TPP 2021):

-diagnostic sensitivity > 90% for detection of isoniazid and fluoroquinolone resistance and ≥ 80% sensitivity for detection of amikacin resistance when measured against the pDST reference standard;

-analytical specificity ≥ 98% for any tuberculosis drug for which the test is able to identify resistance when compared with gDST as the reference standard.

Nonetheless, several challenges and questions need to be considered.

Xpert MTB/XDR must first detect tuberculosis, even if an individual is already tuberculosis-positive by another test, before it can generate a resistant or susceptible result. Our ability to assess Xpert MTB/XDR accuracy for detection of pulmonary tuberculosis was limited by the available data, which we considered to be at high risk of bias due to selective participant recruitment. As Xpert MTB/XDR is likely to be used as a follow-on test to an initial test that detects tuberculosis and rifampicin resistance (i.e. Xpert . This issue, which is a problem with MTBDRsl (a line probe assay), is becoming increasingly important as we seek to expand rapid DST (direct testing), including to those who are paucibacillary (tuberculosis disease caused by a small number of bacteria) and smear-negative and in whom tuberculosis detection by reflex DST would therefore be challenging. Our review had limited data to assess the number of people with tuberculosis who were missed (not detected as tuberculosis-positive by Xpert MTB/XDR to begin with), and would have drug susceptibility results uncharacterised by Xpert MTB/XDR.

In our review, in people with smear-negative specimens, Xpert MTB/ XDR sensitivity (95% CI) for detection of pulmonary tuberculosis was 94% (87% to 98%) (based on one study) and may have been overestimated. We considered this study to have high risk of bias for participant selection. In contrast, a recent Cochrane Review found, in smear-negative (culture-positive) specimens, summary sensitivity of 77.5% (67.6 to 85.6) for Xpert MTB/RIF Ultra and 60.6% (48.4 to 71.7) for Xpert MTB/RIF (7 studies) (Zifodya 2021).

We did not have su icient data to assess Xpert MTB/XDR accuracy for detection of pulmonary tuberculosis in people with and without previous tuberculosis treatment. This is an important concern as the test may report results for drug resistance in people who are detected as MTB-positive, but are in fact culture-negative. The related tests, Xpert MTB/RIF (Theron 2016a) and Xpert MTB/RIF Ultra (Mishra 2020), have diminished specificity in people with previous tuberculosis treatment. Importantly, since people with a history of tuberculosis have a higher risk of drug resistance compared to people who have not had tuberculosis before (WHO Global Tuberculosis Report 2021), DST is more likely to be done in this group.

Regarding detection of ethionamide resistance, Xpert MTB/XDR accuracy is based only on the detection of mutations in the inhA promoter region. Hence this limits the test's value in decision making for ruling-out resistance.

Heteroresistance, the clinical significance of which is uncertain, can be challenging for molecular tests to detect (pDST is generally the best method for detecting minority populations) and may in part explain Xpert MTB/XDR false-negative results. However, Cochrane Database of Systematic Reviews more data are needed on the ability of Xpert MTB/XDR to detect heteroresistance.

Finally, we wish to underscore that an all-in-one test for tuberculosis drug resistance would be highly desirable. However, detecting resistance to additional drugs using Xpert MTB/XDR may not be technologically feasible without great expense or loss of other gene targets.

We were unable to perform several analyses as originally intended in the protocol because the paucity of data precluded pre-specified investigations of heterogeneity. When we observed heterogeneity and could not explore potential sources of heterogeneity, we took this into account when deciding whether to downgrade for inconsistency.

For tuberculosis detection, as assessed by QUADAS-2, in the patient selection domain, we considered all study cohorts (100%) to have high risk of bias. The high proportion (> 90%) of participants with tuberculosis suggests that there was selective recruitment. For drug resistance detection, in the reference standard domain, both studies had low risk of bias for resistance to isoniazid, fluoroquinolones, and amikacin, and high risk of bias for resistance to ethionamide (for both pDST and gDST). Both studies used the critical concentrations for pDST currently recommended by the WHO.

The findings in this review were based on comprehensive searching, strict selection criteria, and standardized data extraction. To identify studies, we searched multiple databases up to 23 September 2021 without language restriction. However, we acknowledge that we may have missed studies despite the comprehensive search. We corresponded with primary study authors to obtain additional data and information that was missing from the papers. The small number of studies and small number of participants in several of the analyses a ected the precision of the results.

Culture is regarded as the best available reference standard for the bacteriological confirmation of pulmonary tuberculosis and was the reference standard for detection of pulmonary tuberculosis in this review. Liquid culture is considered to be more sensitive than solid culture (Lewinsohn 2017). Liquid culture or both solid and liquid culture were the reference standards in these analyses.

As recommended by the WHO, we used culture-based pDST as the main reference standard for isoniazid resistance, fluoroquinolone resistance, and amikacin resistance (WHO TPP 2021). Culture involves growing an inoculum (the introduction of the bacteria into a culture medium) in the absence of a drug. This could lead to resistant bacteria present in the original specimen diminishing below the limit of detection of the reference standard method due to competition with the other drug-susceptible bacteria in the inoculum.

We used gDST as the main reference standard for ethionamide resistance because there is considerable overlap in the minimum inhibitory concentrations of M tuberculosis isolates with and without resistance-causing variants and a pDST reference standard might not correctly classify the target condition. Ethionamide resistance caused by inhA mutations is detected by the Xpert MTB/ XDR, however, the test may not detect all variants of ethionamide resistance. We note that the gDST reference standard used only included the inhA promoter.

For detection of pulmonary tuberculosis, owing to inclusion of participants based on Xpert MTB/RIF-and Xpert MTB/RIF Ultrapositive results, we had high concern about applicability of the findings to the review question. For detection of drug resistance, the two multicentre studies (reporting on six study cohorts) took place at sites located in high MDR/rifampicin-resistant tuberculosis burden countries. However, two study cohorts were in India and two were in South Africa, possibly limiting applicability to other settings.

The review findings suggest that Xpert MTB/XDR provides accurate results for detection of isoniazid and fluoroquinolone resistance and can assist with selection of an optimal treatment regimen. Given that Xpert MTB/XDR targets a limited number of resistance variants in specific genes, the test may perform di erently in di erent settings. Findings in this review should, therefore, be interpreted with caution. Xpert MTB/XDR sensitivity for ethionamide resistance detection was based only on detection of mutations in the inhA promoter region by Xpert MTB/XDR, a known limitation. High risk of bias limits our confidence in Xpert MTB/XDR accuracy for pulmonary tuberculosis.

The impact of Xpert MTB/XDR is expected to be a ected by the test's ability to detect tuberculosis (required for drug susceptibility testing (DST)), prevalence of resistance to a given drug, health care infrastructure, and access to other tests. 

The CIDG editorial base is funded by UK aid from the UK government for the benefit of low-and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government's o icial policies. The following people conducted the editorial process for this article:

• Cochrane Database of Systematic Reviews on-tuberculosis-module-3-diagnosis---rapid-diagnostics-fortuberculosis-detection (accessed 12 October 2021).

World Health Organization.WHO consolidated guidelines on tuberculosis. Module 4: treatment -drug-resistant tuberculosis treatment, June 2020. who.int/publications/i/ item/9789240007048 (accessed 1 July 2020).

World 

World Health Organization.Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020; CC BY-NC-SA 3.0 IGO. who.int/ publications/i/item/meeting-report-of-the-who-expertconsultation-on-the-definition-of-extensively-drug-resistanttuberculosis (accessed 27 January 2021).

World Health Organization.Global tuberculosis report 2020. who.int/tb/publications/global_report/en/ (accessed 19 October 2020).

World Health Organization.Global tuberculosis report 2021. www.who.int/publications/digital/global-tuberculosisreport-2021 (accessed 18 October 2021).

World Health Organization.WHO operational handbook on tuberculosis. 

The composite reference result was considered drug resistant if the pDST was reported as drug resistant or the sequencing results had detected a drug associated resistant mutation. The composite reference result was considered drug susceptible when both pDST reported drug susceptibility and sequencing did not detect a drug associated resistant mutation.

Analyses were undertaken where sequencing data associated with the specimen were reviewed to identify the location and type of mutations present for the drug resistance targets or if the specimen was wild type. The intent of the eligibility criteria was that all specimens used for testing would be characterized and have data available prior to enrolment; however, this was not possible as many specimens available at the study sites had MTB culture results, but did not have other data required. Study sites attempted to complete any missing pDST, sequencing, and Xpert MTB/RIF or Xpert MTB/RIF Ultra testing in parallel with Xpert MTB/XDR testing during the study.

Sequencing method: China -Sanger Sequencing: targeted genes in supernatant DNA were amplified by designated primers and sent for Sanger sequencing; South Africa -Whole Genome Sequencing using NGS on the Illumina MiSeq using paired end sequencing methodology (2 x 300bp).

Was a consecutive or random sample of patients enrolled?

No Was a case-control design avoided?

Did the study avoid inappropriate exclusions?

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

Yes If a threshold was used, was it pre-specified?

Omar 2020 (Continued) Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

Could the patient flow have introduced bias?

Omar 2020 (Continued) 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it prespecified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Omar 2020 China (Continued) Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

Low risk

Patient Sampling Cross-sectional, the manner of participant selection was not random or consecutive For drug resistance detection, MTB positive specimens were characterized by pDST and gDST prior to or during the study Patient characteristics and setting Presenting signs and symptoms: not reported; archived frozen raw sputum or sputum sediment specimens Exclusions: specimens that had been previously thawed were excluded; < 1 mL of frozen sputum sediment or < 2 mL of raw sputum The composite reference result was considered drug resistant if the pDST was reported as drug resistant or the sequencing results had detected a drug associated resistant mutation. The composite reference result was considered drug susceptible when both pDST reported drug susceptibility and sequencing did not detect a drug associated resistant mutation.

Discrepant analysis was undertaken where sequencing data associated with the specimen were reviewed to identify the location and type of mutations present for the drug resistance targets or if the specimen was wild type. The intent of the eligibility criteria was that all specimens used for testing would be characterized and have data available prior to enrolment; however, this was not possible as many specimens available at the study sites had MTB culture results, but did not have other data required. Study sites attempted to complete any missing pDST, sequencing, and Xpert MTB/RIF or Xpert MTB/RIF Ultra testing in parallel with Xpert MTB/XDR testing during the study.

Sequencing method: South Africa -Whole Genome Sequencing using NGS on the Illumina MiSeq using paired end sequencing methodology (2 x 300bp) 

Are there concerns that the included patients and setting do not match the review question?

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it prespecified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Omar 2020 South Africa (Continued) Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Did all patients receive the same reference standard?

Were all patients included in the analysis?

Could the patient flow have introduced bias?

Omar 2020 South Africa (Continued) 

Patient Sampling Cross-sectional, consecutive, prospective Participants were prescreened for pulmonary tuberculosis symptoms and the presence of at least one risk factor for drug-resistant tuberculosis. Participants who met screening criteria received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those found to be Xpert MTB/RIF MTBC-positive or Xpert MTB/RIF Ultra MTBC-positive were enrolled. More than half of the population was also preselected for rifampicin resistance (and not just pulmonary tuberculosis). Screening was random and enrolment was consecutive and sequential for the two phases Patient characteristics and setting Presenting signs and symptoms: symptoms suggestive of pulmonary tuberculosis, i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis), and at least one of the following.

-Previously received > 1 month of treatment for a prior tuberculosis episode or -Failing TB treatment with positive sputum smear or culture after ≥ 3 months of a standard TB treatment or -Had close contact with a known drug-resistant TB case or -Newly diagnosed with MDR-TB within the last 30 days or -Previously diagnosed with MDR-TB and failed TB treatment with positive sputum smear or culture after ≥ 3 months of a standard MDR-TB treatment regimen There was 1 indeterminate result for amikacin resistance in a specimen that was amikacin resistant by pDST. This specimen was gDST susceptible.

Authors' judgement Risk of bias Applicability concerns

Was a consecutive or random sample of patients enrolled?

Yes Was a case-control design avoided?

Yes Did the study avoid inappropriate exclusions?

High risk

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it prespecified?

Could the conduct or interpretation of the index test have introduced bias?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

Could the patient flow have introduced bias?

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Patient Sampling Cross-sectional, consecutive, prospective Participants were prescreened for pulmonary tuberculosis symptoms and the presence of at least one risk factor for drug-resistant tuberculosis. Participants who met screening criteria received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those found to be Xpert MTB/RIF MTBC-positive or Xpert MTB/RIF Ultra MTBC-positive were enrolled. More than half of the population was also preselected for rifampicin resistance (and not just pulmonary tuberculosis). Screening was random and enrolment was consecutive and sequential for the two phases Patient characteristics and setting Presenting signs and symptoms: symptoms suggestive of pulmonary tuberculosis, i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis), and at least one of the following.

- 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Yes If a threshold was used, was it prespecified?

Low risk

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin 

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

DOMAIN 3: Reference Standard

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

Low risk

Patient Sampling Cross-sectional, consecutive, prospective Participants were prescreened for pulmonary tuberculosis symptoms and the presence of at least one risk factor for drug-resistant tuberculosis. Participants who met screening criteria received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those found to be Xpert MTB/RIF MTBC-positive or Xpert MTB/RIF Ultra MTBC-positive were enrolled. More than half of the population was also preselected for rifampicin resistance (and not just pulmonary tuberculosis). Screening was random and enrolment was consecutive and sequential for the two phases Patient characteristics and setting Presenting signs and symptoms: symptoms suggestive of pulmonary tuberculosis, i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis), and at least one of the following.

-Previously received > 1 month of treatment for a prior tuberculosis episode or 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

If a threshold was used, was it prespecified?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Penn-Nicholson 2021 India (New Delhi) (Continued) Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin Cochrane Database of Systematic Reviews

Was there an appropriate interval between index test and reference standard?

Yes Did all patients receive the same reference standard?

Were all patients included in the analysis?

Could the patient flow have introduced bias?

Low risk

Patient Sampling Cross-sectional, consecutive, prospective Participants were prescreened for pulmonary tuberculosis symptoms and the presence of at least one risk factor for drug-resistant tuberculosis. Participants who met screening criteria received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those found to be Xpert MTB/RIF MTBC-positive or Xpert MTB/RIF Ultra MTBC-positive were enrolled. More than half of the population was also preselected for rifampicin resistance (and not just pulmonary tuberculosis). Screening was random and enrolment was consecutive and sequential for the two phases Patient characteristics and setting Presenting signs and symptoms: symptoms suggestive of pulmonary tuberculosis, i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis), and at least one of the following.

- 

Are there concerns that the included patients and setting do not match the review question?

Low concern DOMAIN 2: Index Test (All tests)

Were the index test results interpreted without knowledge of the results of the reference standard?

Yes If a threshold was used, was it prespecified?

Could the conduct or interpretation of the index test have introduced bias?

Are there concerns that the index test, its conduct, or interpretation differ from the review question?

Is the reference standards likely to correctly classify the target condition?

Were the reference standard results interpreted without knowledge of the results of the index tests?

Could the reference standard, its conduct, or its interpretation have introduced bias?

Are there concerns that the target condition as defined by the reference standard does not match the question?

Low concern DOMAIN 4: Flow and Timing 

Patient Sampling Cross-sectional, consecutive, prospective Participants were prescreened for pulmonary tuberculosis symptoms and the presence of at least one risk factor for drug-resistant tuberculosis. Participants who met screening criteria received prior testing with Xpert MTB/RIF or Xpert MTB/RIF Ultra and those found to be Xpert MTB/RIF MTBC-positive or Xpert MTB/RIF Ultra MTBC-positive were enrolled. More than half of the population was also preselected for rifampicin resistance (and not just pulmonary tuberculosis). Screening was random and enrolment was consecutive and sequential for the two phases Patient characteristics and setting Presenting signs and symptoms: symptoms suggestive of pulmonary tuberculosis, i.e. persistent cough (≥ 2 weeks) or as per local definition of suspected pulmonary tuberculosis), and at least one of the following.

- 

The term reflex test refers to a diagnostic approach in which an initial test meets predetermined criteria (e.g. outside of the normal range), and a second test is performed automatically, usually without a request from the health care worker. For example, a urinalysis may be followed by a culture (reflex test) if in the urine, the presence of nitrites is detected or the number of white blood cells is increased suggesting an infection. In the context of tuberculosis, culture may be used as a reflex test in a person living with HIV who has a Xpert MTB/RIF Ultranegative result.

A region of the Mycobacterium tuberculosis genome where mutations commonly cause resistance to a specific drug.

Gene target included in the Xpert MTB/XDR test to detect mutations that confer resistance to second-line injectable drugs, amikacin, kanamycin, and capreomycin.

Technique for DNA sequencing based upon the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication, also known as 'the chain termination method'.

The process for detecting predetermined mutations in DNA or genomic regions.

The process of determining the complete genome sequence for a given organism (tuberculosis bacteria) at one time through nextgeneration sequencing methods. This method can determine the order of most nucleotides in a given genome and detect any variations relative to a reference genome using bioinformatics analyses.

Adapted from National Human Genome Research Institute 2022.

Trusted evidence. Informed decisions. Better health.

( TITLE-ABS-KEY ( ( cartridge AND test* ) OR ( molbio OR truenat OR cepheid OR xpert* OR bioneer OR hain ) OR genexpert* OR point-of-care AND system* ) ) AND ( ( TITLE-ABS-KEY ( tuberculosis AND ( drug AND resistan* OR multidrug AND resistan* OR mdr OR xdr ) ) ) OR ( TITLE-ABS-KEY ( tuberculosis AND ( ( isoniazid AND resist* ) OR ( ethionamide AND resist* ) OR ( amikacin AND resist* ) OR ( fluoroquinolone AND resist* ) OR ( second-line AND injectable AND drug AND resist* ) ) ) ) ) AND ( LIMIT-TO ( PUBYEAR , 2021 ) 

Risk of bias: could the selection of patients have introduced bias?

We answered yes if the study enrolled a consecutive or random sample of eligible participants; no if the study selected participants by convenience; and unclear if the study did not report the manner of participant selection or we could not determine this.

We answered yes for all studies.

We answered yes if the study included both smear-positive and smear-negative participants; no if the study included primarily or exclusively smear-positive or smear-negative participants; and unclear if we could not determine this. If, at the time of specimen collection, participants were receiving tuberculosis treatment, we answered no because treatment reduces the culturability of M tuberculosis quicker than it reduces the amount of MTB DNA. Treatment therefore confounds the relationship between Xpert MTB/XDR-positivity and culturepositivity (the reference standard), potentially leading to underestimation of specificity. We also judged high-risk of bias if we thought most participants were enrolled based on known rifampicin resistance.

We considered low concern if the included patients matched the review question; high concern if the included patients did not match the review question; and unclear concern if we could not determine. Our assessment included consideration of prior testing and the clinical setting. We answered low concern if participants were people with presumed pulmonary tuberculosis; high concern if participants received prior testing and were included based on a positive Xpert MTB/RIF or Xpert MTB/RIF Ultra result; and unclear concern if participants received prior testing but we could not tell if inclusion was based on a positive Xpert MTB/RIF or Xpert MTB/RIF Ultra result. We answered low concern if participants were evaluated as outpatients (with either expectorated or induced sputum) in local hospitals or primary care centres. We answered high concern if participants were evaluated exclusively as inpatients in tertiary care centres. We answered unclear concern if the clinical setting was not reported or there was insu icient information to make a decision. We also answered unclear concern if testing was performed at a central-level laboratory and the clinical setting was not reported or if, for example, it was di icult to determine whether the laboratory provided services mainly to very sick people or people with a broader clinical spectrum of illness. We also answered high concern if patients were on treatment or their treatment status was unclear, as such patients have already been diagnosed with tuberculosis.

Risk of bias: could the selection of participants have introduced bias? 

We answered the same as for detection of tuberculosis.

We answered yes if the study enrolled people with tuberculosis with suspected or su iciently high pretest probability (per World Health Organization guidelines) for resistance to isoniazid, second-line drugs, or both isoniazid and second-line drugs; no if the study enrolled people with tuberculosis with confirmed previously known resistance to the drug in question; and unclear for all other scenarios or if it was not clearly reported. We considered that accuracy studies may have a cross-sectional design even when the reference standard is performed before the index test if both cases and controls are sampled from a single source population.

Signalling question 3: did the study avoid inappropriate exclusions?

We answered yes for people who were previously treated for tuberculosis. We answered no if people who were previously treated were excluded. People previously tested for tuberculosis have a higher risk of having drug resistance and are likely to be the target population for initial use of Xpert MTB/XDR. If people with samples known to be heteroresistant (a mix of susceptible and resistant tuberculosis strains in the specimen) were excluded, which is particularly relevant for the fluoroquinolones, we answered answer no. We answered unclear if we could not determine this.

Applicability: are there concerns that the included participants and setting do not match the review question?

We answered low concern if the selected clinical specimens or isolates matched the review question, which reflects the way the test will be used in practice. We answered high concern if the selected specimens or isolates did not represent those for whom the test will be used in practice, such as in people who do not require investigation for resistance to the drugs in question. We answered unclear concern if we could not determine this.

Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard?

We answered yes for all studies since Xpert MTB/XDR results are automatically generated and the user is provided with printable test results, thus, avoiding subjective interpretation.

Signalling question 2: if a threshold was used, was it pre-specified?

We answered yes for all studies.

Applicability: are there concerns that the index test, its conduct, or its interpretation di er from the review question?

Variations in test technology, execution, or interpretation may a ect estimates of the diagnostic accuracy of a test. We judged the study of low concern for applicability if the test was performed as recommended by the manufacturer. We judged the study of high concern if the test was applied di erently than recommended by the manufacturer, for example, if the test was applied to summary sputa. We judged the study of unclear concern if we could not determine this.

Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard?

We answered yes for all studies since Xpert MTB/XDR results are automatically generated and the user is provided with printable test results, thus, avoiding subjective interpretation.

Signalling question 2: if a threshold was used, was it pre-specified?

We answered yes for all studies.

Applicability: are there concerns that the index test, its conduct, or its interpretation di er from the review question?

We recorded the same judgements as for detection of pulmonary tuberculosis.

Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? 

Signalling question 1: is the reference standard likely to correctly classify the target condition?

We answered yes for all studies because a microbiological reference standard for M tuberculosis is a criterion for inclusion in the review.

We answered yes if the reference test provided an automated result (e.g. MGIT 960), blinding was explicitly stated, or it was clear that the reference standard was performed at a separate laboratory or performed by di erent people (or both). We answered no if the study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/XDR test result. We answered unclear if we could not determine this.

Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?

We answered high concern if a type of culture was not used as part of the reference standard, because studies that include only DNA-based tests do not directly measure live M tuberculosis. We answered low concern if culture was performed. We answered unclear concern if we could not determine this.

Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?

We considered the reliability of the di erent reference standards for the di erent drugs (Heyckendorf 2018). For pDST, we answered yes if the reference test provided an automated result (e.g. if liquid culture was used as in MGIT 960 DST), blinding was explicitly stated, or it was clear that the reference test was performed at a separate laboratory, or performed by di erent people, or both. Of note, pDST on solid media is not automated. We answered no if the study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/XDR test result. We answered unclear if we could not determine this. For gDST, we answered yes for all studies since the results for the reference standard are automated.

We added the following signalling question.

Signalling question 3: Were the index test and reference standard performed using the same material (clinical specimen or sediment, or cultured isolate)?

Phenotypic DST (pDST) and genotypic DST (gDST) for reference standard testing can be performed on an isolate that has undergone (potentially multiple rounds) of culture in drug-free media. This may lead to the depletion of resistant strains present in the original specimen (which would have been used for the Xpert MTB/XDR testing if direct testing was performed) and cause discrepant results. We think this is an important question as it addresses heteroresistance, which o en explains discordance between genotypic and phenotypic results.

For direct testing of a clinical specimen by Xpert MTB/XDR: we answered yes if the reference test was performed directly on the same clinical specimen; no if the reference standard was performed on a culture isolate; and unclear if we could not determine this. For indirect testing of a culture isolate by Xpert MTB/XDR: we answered yes if the reference test was performed on the same culture isolate (e.g. indirect sequencing); no if the reference standard was performed on a di erent culture isolate, or specimen; and unclear if we could not determine this.

Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?

We judged applicability of low concern for all studies because specimens to be subsequently tested for drug resistance will have already been identified as M tuberculosis complex positive. 

In most studies, we expected the reference standard to be performed at the same time as Xpert MTB/XDR. However, in some studies, the reference standard may have been performed on a di erent sample collected at an earlier time. This case applies to some cultured isolates, whose drug susceptibility profile might have been confirmed before Xpert MTB/XDR was available. We answered yes if Xpert MTB/XDR and the reference standard were performed at the same time or were separated by less than 14 days. We answered no if Xpert MTB/XDR and the reference standard were not performed at the same time and were separated by 14 days or more. As people suspected of second-line drug resistance are o en receiving treatment for tuberculosis, it is possible that variation in the microbial population of specimens collected at di erent time points may occur. We answered unclear if we could not determine this.

Signalling question 2: did all patients receive the same reference standard?

We answered yes if the reference standard was applied to all participants or a random sample of participants, no if the reference standard was only applied to a selective group of participants, and unclear if it was not stated in the paper or if the authors failed to answer this question.

We determined the answer to this question by comparing the number of participants enrolled with the number of participants included in the 2×2 tables. We noted if the study authors reported the number of inconclusive test results. We answered yes if the number of participants enrolled was clearly stated and corresponded to the number presented in the analysis or if exclusions were adequately described. We answered no if there were participants missing or excluded from the analysis and there was no explanation given. We answered unclear if insu icient information was given to assess whether participants were excluded from the analysis.

We answered the same as for detection of pulmonary tuberculosis.

Judgements for risk of bias assessments for a given domain.

• If we answered all signalling questions for a domain yes, then we judged risk of bias as low.

• If we answered all or most signalling questions for a domain no, then we judged risk of bias as high.

• If we answered only one signalling question for a domain no, we discussed further the risk of bias judgement.

• If we answered all or most signalling questions for a domain unclear, then we judged risk of bias as unclear.

• If we answered only one signalling question for a domain unclear, we discussed further the risk of bias judgement for the domain.

In Penn-Nicholson 2021, among specimens with results reported as Xpert MTB/XDR INDETERMINATE, we could not determine the proportion that were resistant or susceptible by the pDST reference standard.

One study reported information about when Xpert MTB/XDR did not detect tuberculosis to begin with (missed cases) (Omar 2020). Cochrane Database of Systematic Reviews Appendix 6. Xpert MTB/XDR for detection of resistance to kanamycin and capreomycin All concentrations are in mg/L and apply to the proportion method with 1% as the critical proportion. Unless otherwise stated, they are critical concentrations (CCs), as opposed to clinical breakpoints (CBs). The clinical breakpoint is used to guide individual clinical decisions in patient treatment.

MGIT is proposed as the reference method for performing DST for second-line tuberculosis agents.

Protocol first published: Issue 6, 2021

SP, GRD, MDV, MC, KRS, and GT dra ed the review.

MC and KRS wrote the statistical analysis section.

All review authors (SP, GRD, MC, MDV, SGS, RW, KRS, and GT) read and approved the final review dra .

SP received funding from USAID, administered by the World Health Organization (WHO) Global Tuberculosis Programme, Switzerland.

KRS received funding from USAID, administered by the WHO Global Tuberculosis Programme, Switzerland. In addition, she has received financial support from Cochrane Infectious Diseases (UK), McGill University (Canada), Baylor College of Medicine (USA), Maastricht University (the Netherlands), and the WHO Global Tuberculosis Programme (Switzerland) for the preparation of related systematic reviews and educational materials; consultancy fees from FIND, Switzerland (for the preparation of systematic reviews and GRADE tables); consultancy fees from Stellenbosch University, South Africa (for guidance on evidence syntheses), and honoraria, and travel support to attend WHO guideline meetings.

GRD received funding from USAID, administered by the WHO Global Tuberculosis Programme, Switzerland.

MC has no known conflicts of interest.

MDV is employed by the Foundation for Innovative New Diagnostics (FIND). FIND has conducted studies and published on Xpert MTB/RIF as part of a collaborative project between FIND, a Swiss non-profit, Cepheid, a US company, and academic partners. The product arising through this partnership was developed under a contract that obligated FIND to pay for development costs and trial costs and Cepheid to make the test available at specified preferential pricing to the public sector in low-and middle-income countries. In addition, FIND conducted studies for the Xpert MTB/RIF Ultra assay, which have also been published.

SGS was employed by the Foundation for Innovative New Diagnostics (FIND) while conducting the review. FIND has conducted studies and published on Xpert MTB/XDR and Xpert MTB/RIF as part of a collaborative project between FIND, a Swiss non-profit, Cepheid, a US company, and academic partners. Regarding Xpert MTB/RIF, the product developed through this partnership was developed under a contract that obligated FIND to pay for development costs and trial costs and Cepheid to make the test available at specified preferential pricing to the public sector in low-and middle-income countries. In addition, FIND conducted studies for the Xpert MTB/RIF Ultra assay, which have also been published.

RW has no known conflicts of interest.

GT received funding from USAID, administered by the WHO Global Tuberculosis Programme, Switzerland. In addition, he has received inkind research consumable donations provided to employer by Cepheid to work on Xpert Cochrane Database of Systematic Reviews XDR) for diagnostic accuracy evaluations for tuberculosis detection. He is the group Principal Investigator for this work. Cepheid has also loaned instruments to conduct these studies. These studies are on di erent products to those potentially considered for inclusion in this Cochrane Review.

• 

Clinical pathway -Scenario D. Xpert MTB/XDR used for detection of drug resistance in people being treated for pulmonary tuberculosis. We did not identify studies that assessed this role.

-A secondary objective was to compare the diagnostic accuracy of Xpert MTB/XDR by direct testing (whereby Xpert MTB/XDR is tested directly on a sputum specimen) versus indirect testing (whereby Xpert MTB/XDR is run on an M tuberculosis isolate grown from culture). Our plan was to perform these analyses for those studies that made direct comparisons between test evaluations with the same participants by adding a covariate for the type of testing to the model (Takwoingi 2013). However, we only identified one study that compared Xpert MTB/XDR accuracy by direct and indirect testing. Instead, we narratively described these analyses and presented results in forest plots.

-Types of studies. We identified one report at a conference and included this report in the review.

-Conflicts of interest. We had planned to assess conflicts of interest using the Tool for Addressing Conflicts of Interest in Trials (TACIT) (Lundh 2020). However, this tool was not available while we performed the review. We extracted information about industry sponsorship and performed sensitivity analyses by repeating the meta-analyses and excluding the study sponsored by the manufacturer.

-Regarding fluoroquinolone resistance, we had planned to take the following approach. If multiple fluoroquinolones were tested by pDST and at least one was resistant, the patient would be classified as resistant. If no resistant results occurred and a least one pDST susceptible result was present, that patient would be classified as susceptible. However, none of the included studies tested more than one fluoroquinolone by pDST.

-Due to little observed variability in specificity and in the volume of analyses, we chose to present only forest plots, as such plots were more informative than corresponding summary receiver operator characteristics (SROC) plots.

-We did not perform a meta-analysis for Xpert MTB/XDR for pulmonary tuberculosis detection as heterogeneity, in terms of both characteristics of included participants and observed specificity values, would have rendered the summary sensitivity and specificity estimates uninterpretable and potentially misleading.

-We performed meta-analyses to estimate the summary proportion of non-determinate and indeterminate results using the metaprop command in Stata (Version 14) (Stata).

-We wrote in the protocol that we would extract data on discrepant analysis, where in each study, gene sequencing was applied only to resolve discordant Xpert MTB/XDR-pDST results. However, the study cohorts evaluated Xpert MTB/XDR using both pDST and gDST as reference standards and we did not characterize discordant results further.

Ovid MEDLINE(R) and In-Process, In-Data-Review & Other Non-Indexed Citations < 1946 to present

Extensively Drug-Resistant Tuberculosis/ or Tuberculosis, Multidrug-Resistant/ or Tuberculosis, Pulmonary/ or Mycobacterium Tuberculosis

isoniazid or fluoroquinolone or "second-line injectable drug" or SLID) adj3 (monoresist* or mono-resist*))

XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin (Review)

Ltd. on behalf of The Cochrane Collaboration. 91 drug susceptibility test* or drug resistance test* or (rapid adj3 (detect* or test* or diagnos*)) or (poc or poct or "point of care")).mp. resistant tuberculosis/ or extensively drug resistant tuberculosis/ or multidrug resistant tuberculosis

or fluoroquinolone or "second-line injectable drug" or SLID) adj3 (monoresist* or mono-resist*))drug susceptibility test* or drug resistance test* or (rapid adj3 (detect* or test* or diagnos*)) or (poc or poct or

Limit 21 to yrs

#4 (#1) AND #2 and 2021 or 2020 or

#3 (#1) AND #2

#2 (cartridge test*) or (Molbio or Truenat or Cepheid or Xpert* or Bioneer or Hain) or Genexpert* or Point-of-Care System* (Topic)

#1 (tuberculosis AND (drug resistan* or multidrug resistan* or mdr or xdr)) (Topic) or tuberculosis AND (isoniazid resist* or Ethionamide resist* or Amikacin resist* or Fluoroquinolone resist* or Second-line injectable drug resist*

XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin (Review)

Search on: (tuberculosis AND (drug resistan$ or multidrug resistan$ or mdr or xdr)) [Words] and (cartridge test$) or (Molbio or Truenat or Cepheid or Xpert$ or Bioneer or Hain) or Genexpert$ or Point-of-Care System

Multi-Drug Resistant Tuberculosis

ProQuest Dissertations & Theses A&I ab(tuberculosis) AND ab(Xpert or genexpert or cartridge) limit to

Fluoroquinolone resistance Of 530 specimens tested, 498 specimens had an Xpert MTB/XDR MTB DETECTED result. Of these 498 specimens, four (0.8%) had indeterminate results for detection of resistance. By the pDST reference standard, of these four specimens, zero (0%) were resistant and four (100%) were susceptible

Of 709 specimens tested, 657 had an Xpert MTB/XDR MTB DETECTED result. Of these 657 specimens, nine (1.4%) had indeterminate results for detection of resistance

Ethionamide resistance Of 530 specimens tested, 498 specimens had an Xpert MTB/XDR MTB DETECTED result. Of these 498 specimens, none (0%) had an indeterminate result for detection of resistance

Of 709 specimens tested, 657 had an Xpert MTB/XDR MTB Detected result. Of these 657 specimens, one (0.2%) had an indeterminate result for detection of resistance. This specimen was no longer indeterminate upon retesting

Amikacin resistance Of 530 specimens tested, 498 specimens had an Xpert MTB/XDR MTB DETECTED result. Of these 498 specimens, eight (1.6%) had indeterminate results for detection of resistance. By the pDST reference standard, of these eight specimens, zero (0%) were resistant and eight (100%) were susceptible

Of 709 specimens tested, 657 had an Xpert MTB/XDR MTB DETECTED result. Of these 657 specimens, 23 (3.5%) had indeterminate results for detection of resistance

Presented below are all the data for all of the tests entered into the review. Results from the sensitivity analyses (in bold) in which the manufacturer sponsored study was excluded. The population is people irrespective of rifampicin resistance and the reference standard is phenotypic drug susceptibility testing. Study cohorts were treated as distinct units in the meta-analyses. *Prevalence of drug resistance for calculating predictive values was 5%.

Amplification is replication of a deoxyribonucleic acid (DNA) fragment to generate copies. Both the original and the newly synthesized copies can be described as the amplicons.

Cultured isolate refers to M tuberculosis bacteria from a clinical specimen that have been grown. For tuberculosis diagnosis, a volume of the clinical specimen is processed and incubated under conditions that promote M tuberculosis growth. The bacteria that are grown are referred to a cultured isolate.

DNA sequencing is a process to determine the nucleotide (adenine (A), cytosine (C), guanine (G), and thymine (T)) sequence of fragments of DNA. By comparison of DNA sequences from distinct tuberculosis isolates, variations known as mutations can be identified. Some mutations in M tuberculosis are known to be associated with drug resistance.

Drug susceptibility tests determine whether M tuberculosis bacteria are susceptible or resistant to drugs. Testing may be undertaken using phenotypic or genotypic analyses.

Gene target included in the Xpert MTB/XDR test to detect mutations that confer resistance to second-line injectable drugs, amikacin and kanamycin.

Gene target included in the Xpert MTB/XDR test to detect mutations that confer resistance to isoniazid.

Genotypic drug susceptibility testing (gDST) involves detecting predetermined mutations in DNA that are known to make the bacteria resistant to a drug. When mutations causing drug resistance are unknown, gDST is not useful.gDST can be targeted (limited to a certain number of loci for a drug) or genome-wide. Sanger sequencing, a targeted sequencing method, is limited in its depth (x1 vs. x100 for whole genome sequencing). Deep sequencing methods have greater resolution than the Sanger sequencing method. They also appear robust when performed on DNA extracted directly from a specimen (versus a cultured isolate), especially if that specimen is rich in mycobacteria. As with any method that is targeted, targeted gDST will miss phenotypic resistance causing mutations that occur outside of the target, simply because it is not designed to evaluate that region.Genome-wide gDST typically refers to whole genome sequencing. Importantly, although whole genome sequencing could have been performed, some investigators might only use it in a manner equivalent to targeted sequencing of certain regions. For example, if whole genome sequencing coverage was poor in a region known to be important for resistance, but otherwise adequate in other regions important for resistance, whole genome sequencing will serve in this case as a limited form of targeted sequencing. In other words, even though most of the genome may be sequenced, we may not know where to look for resistance associated variants. 

Heteroresistance is defined as resistance to certain drugs in a subset of a larger microbial population that is generally considered susceptible to these drugs according to traditional phenotypic drug susceptibility testing. 

Was microscopy used? 

The summary proportion of Xpert MTB/XDR non-determinate results was estimated to be 2.90% (95% CI: 1.97% to 3.84%).In Omar 2020, upon initial Xpert MTB/XDR testing, of 531 specimens tested, 15 resulted in non-determinate results. There were 10 Error results, one Invalid result, and four No Result results. Therefore, the proportion of non-determinate results upon initial testing was 2.8%. The 15 specimens were retested, and 14 gave valid results. Only one of the 15 retested specimens resulted in an Error following its repeat test. Therefore, the proportion of non-determinate results following retesting was 0.2% (1/531).In Penn-Nicholson 2021, upon initial Xpert MTB/XDR testing, of 709 specimens tested, 21 resulted in non-determinate results. Therefore, the proportion of non-determinate results upon initial testing was 3.0% (21/709). The 21 specimens were retested, and 19 gave valid results. Therefore, the proportion of non-determinate results following retesting was 0.3% (2/709).One study reported Xpert MTB/XDR non-determinate results by smear status (Penn-Nicholson 2021) . In this study, the proportion of Xpert MTB/XDR non-determinate results was 4.2% (9/216) in smear-negative specimens and 2.4% (12/491) in smear-positive specimens.Cochrane Database of Systematic ReviewsThe phenotypic status of non-determinate results was not discernable for either study.

Of 530 specimens tested, 498 specimens had an Xpert MTB/XDR MTB DETECTED result. Of these 498 specimens, two (0.4%) had indeterminate results for detection of resistance. By the pDST reference standard, of these two specimens, two (100%) were resistant and zero (0%) were susceptible (Omar 2020).Of 709 specimens tested, 657 had an Xpert MTB/XDR MTB DETECTED result. Of these 657 specimens, two (0.3%) had indeterminate results for detection of resistance. None were indeterminate upon retesting (Penn-Nicholson 2021).Cochrane Database of Systematic Reviews

We had planned to explore the possible influence of the pre-specified categorical covariates, listed below, by adding these covariates to the meta-analysis models. However, data were insu icient to perform these analyses. Had we performed these analyses, we would have assessed the significance of the di erence in test accuracy according to each covariate by performing a likelihood ratio test comparing models with and without covariate terms.For detection of pulmonary tuberculosis, we had planned to investigate the following potential sources of heterogeneity.• Smear status, smear positive or negative (we described narratively).• HIV status, positive or negative.• Previous tuberculosis treatment, previous treatment or no previous treatment. We changed 'History of tuberculosis treatment' (in the protocol) to 'previous tuberculosis treatment' (in the review). • Treatment status, no treatment or currently receiving treatment.• Treatment response status, culture conversion, yes or no.For detection of drug resistance, we investigated the following potential sources of heterogeneity.• Type of reference standard.• Smear status, positive or negative (we described narratively).• HIV status, positive or negative (we described narratively).• Previous tuberculosis treatment, previous treatment or no previous treatment (we described narratively).In addition, we had planned to investigate specific drugs (e.g. ofloxacin or moxifloxacin) used in the pDST reference standard for determining fluoroquinolone resistance; however data were not available to do this.We had also planned to investigate 'Was the WHO-recommended critical drug concentration used for the pDST reference standard (WHO Critical Concentrations 2018; WHO Critical Concentrations 2021), yes or no? However, the included studies used the currently recommended concentration for each drug.

-For Xpert MTB/XDR for detection of drug resistance against the pDST reference standard, we had planned to perform sensitivity analyses for studies meeting the QUADAS-2 criteria listed below. However, there were only two studies in the review and the sensitivity analyses are less meaningful with few studies.1. Was a consecutive or random sample of participants/specimens enrolled? 2. Were the reference standard results interpreted without knowledge of the results of the index test results? 3. Was the test applied in the manner recommended by the manufacturer (index test domain, low concern about applicability)?Questions numbered 2 and 3 were satisfied by all studies.-For Xpert MTB/XDR for detection of resistance to isoniazid and fluoroquinolones in people irrespective of rifampicin resistance, we performed sensitivity analyses by repeating the meta-analyses and excluding the study (reporting on two study cohorts) sponsored by the manufacturer. For detection of resistance to ethionamide and amikacin in people with known rifampicin resistance, we did not perform sensitivity analyses because the main analyses included only one study (reporting on four study cohorts), which was not sponsored by the manufacturer.